Polyamine Depletion Strategies in Cancer: Remodeling the Tumor Immune Microenvironment to Enhance Anti-Tumor Responses.
JournalMedical sciences (Basel, Switzerland)
MetadataShow full item record
AbstractPolyamine biosynthesis is frequently dysregulated in cancers, and enhanced flux increases intracellular polyamines necessary for promoting cell growth, proliferation, and function. Polyamine depletion strategies demonstrate efficacy in reducing tumor growth and increasing survival in animal models of cancer; however, mechanistically, the cell-intrinsic and cell-extrinsic alterations within the tumor microenvironment underlying positive treatment outcomes are not well understood. Recently, investigators have demonstrated that co-targeting polyamine biosynthesis and transport alters the immune landscape. Although the polyamine synthesis-targeting drug 2-difluoromethylornithine (DFMO) is well tolerated in humans and is FDA-approved for African trypanosomiasis, its clinical benefit in treating established cancers has not yet been fully realized; however, combination therapies targeting compensatory mechanisms have shown tolerability and efficacy in animal models and are currently being tested in clinical trials. As demonstrated in pre-clinical models, polyamine blocking therapy (PBT) reduces immunosuppression in the tumor microenvironment and enhances the therapeutic efficacy of immune checkpoint blockade (ICB). Thus, DFMO may sensitize tumors to other therapeutics, including immunotherapies and chemotherapies.
polyamine blocking therapy
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/19283
- Polyamine-blocking therapy reverses immunosuppression in the tumor microenvironment.
- Authors: Hayes CS, Shicora AC, Keough MP, Snook AE, Burns MR, Gilmour SK
- Issue date: 2014 Mar
- Polyamine Blocking Therapy Decreases Survival of Tumor-Infiltrating Immunosuppressive Myeloid Cells and Enhances the Antitumor Efficacy of PD-1 Blockade.
- Authors: Alexander ET, Mariner K, Donnelly J, Phanstiel O 4th, Gilmour SK
- Issue date: 2020 Oct
- Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma.
- Authors: Bassiri H, Benavides A, Haber M, Gilmour SK, Norris MD, Hogarty MD
- Issue date: 2015 Jul
- Inhibition of Polyamine Biosynthesis Using Difluoromethylornithine Acts as a Potent Immune Modulator and Displays Therapeutic Synergy With PD-1-blockade.
- Authors: Dryja P, Fisher C, Woster PM, Bartee E
- Issue date: 2021 Oct 1
- Molecular mechanisms of polyamine analogs in cancer cells.
- Authors: Huang Y, Pledgie A, Casero RA Jr, Davidson NE
- Issue date: 2005 Mar